Professional Documents
Culture Documents
Poster presentations / International Journal of Gynecology & Obstetrics 107S2 (2009) S413S729
P113
Does substance abuse increase prematurity and low
birth weight?
K. Khashia1 , T. Breslin1 , N. Swamy2 , J. Patrick1 . 1 Royal Oldham
Hospital, 2 Royal Glamorgan Hospital
Background: Poly substance abuse tends to be common. Substance
abuse can be associated with IUGR, pre-term labour, and low birth
weight of babies. These women do need a lot of social support in
their pregnancy and hence involvement of drug laison midwife is
vital.
Aims:
To assess obstetric and neonatal outcome of women with
substance abuse;
To assess whether substance abuse is associated with IUGR, preterm labour, and low birth weight of babies;
To assess if referral was made to the drug liason midwife.
Methodology:
Patients identied Euroking maternity database;
Review of 66 case notes of women with substance abuse in
pregnancy across 3 hospitals in the Penine Acute NHS trust
(Rochdale informary/North Manchester general hospital and
Royal Oldham hospital);
Time period 1/1/2006 to 30/06/2007.
Standard:
All women with substance abuse should be under consultant lead
shared care;
All women should have growth scan at 28 weeks;
All women should be referred to drug liaison midwife.
Results: Poly substance abuse was common, with most of them
using cannabis(76%) and methadone use in 20%. 24% were teenage
pregnancies. 23% booked late after 20wks. 83% were under
consultant led shared care and drug laison midwife was involved
in the care of 43%. There was history of smoking in 88% and
alcohol intake in 44%. 14% were subjected to domestic violence.
Prematurity and lowbirth weight were noted in 15%. There were
suspected congenital anomalies in 3%. The caesarean section rate
was 16%.
Conclusion: Consultant led shared care and involvement of a drug
laison midwife to offer support does improve the outcome of a
high risk pregnancy.
P114
Maternal serum placental protein (PP13) as a potential marker
for early pre-eclapsia
X. Ma, B. Chen, X. Xin. Department of Ob/Gyn, Xijing Hospital, Fourth
Military Medical University
Objective: To evaluate rst-trimester maternal serum placental
protein 13 as a screening test for preeclampsia (PE).
Methods: In prospective nested casecontrol studies, PP13 levels
were measured during 1st, 2nd and 3rd trimesters in women who
developed PE vs matched controls.
Results: Placental protein 13 (PP13) is a 32-kd dimer protein
produced only in the placenta which belongs to one of 56 members
in one super family. PP13 is thought to be involved in normal